Phase II DESTINY-CRC01: Trastuzumab Deruxtecan in Patients With HER2-Expressing Metastatic Colorectal Cancer

May 29-31, 2020; Online at meetings.asco.org/am
In patients with previously treated HER2+ metastatic CRC, T-DXd associated with a response rate of 45% and durable responses.
Format: Microsoft PowerPoint (.ppt)
File Size: 256 KB
Released: June 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Daiichi Sankyo, Inc.

Related Content

In this short slideset from Clinical Care Options (CCO), experts review neoadjuvant/adjuvant therapy for resectable pancreatic cancer

person default Paul E. Oberstein, MD Released: March 1, 2021

Video of expert discussion on neoadjuvant/adjuvant therapy for resectable pancreatic cancer from Clinical Care Options (CCO)

person default Paul E. Oberstein, MD
Program Director
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 1, 2021 Expired: February 28, 2022

In this short slideset from Clinical Care Options (CCO), experts review second-line treatment options for advanced pancreatic cancer

Andrew H. Ko, MD Released: February 19, 2021

Video of expert discussion of second-line therapy for metastatic pancreatic cancer from Clinical Care Options (CCO)

Andrew H. Ko, MD
Program Director
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 19, 2021 Expired: February 18, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue